Article Data

  • Views 525
  • Dowloads 168

Original Research

Open Access

The effect of other high-risk HPV types on cervical intraepithelial neoplasia and cancer

  • Seda Şahin Aker1,*,
  • Batuhan Bakırarar2
  • Andrea Tinelli3
  • Fırat Ortaç4

1Department of Gynecologic Oncology, Kayseri City Education and Training Hospital, 38080 Kayseri, Turkey

2Department of Biostatistics, Ankara University Faculty of Medicine, 06230 Ankara, Turkey

3Obstetrics and Gynecology Department, Veris delli Ponti Hospital, Scorrano, 73020 Lecce, Italy

4Department of Gynecologic Oncology, Ankara University Faculty of Medicine, 06620 Ankara, Turkey

DOI: 10.31083/j.ejgo4301008 Vol.43,Issue 1,February 2022 pp.10-16

Submitted: 21 October 2021 Accepted: 10 January 2022

Published: 15 February 2022

*Corresponding Author(s): Seda Şahin Aker E-mail:


Objective: Cervical cancer is an serious healthcare problem with a high mortality rate. High-risk Human papillomavirus (HPV) geno-types, especially HPV 16, 31, 33, and 18, are the leading cause of cervical cancer and cervical intraepithelial neoplasia. Cervical cancer screening programs, especially ones that are HPV-based, have gained prominence in many countries. Herein, we evaluated the effect of other high-risk (hr) HPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) with normal cytology on cervical intraepithelial neoplasia and cancer. Methods: 9015 patients were screened via HPV typing and cytology. 520 patients with high-risk HPV positivity, aged 25–65, and unvaccinated for HPV were included in the study. Patients with high-risk HPV DNA positivity and cytologic abnor-mality, HPV 16–18 positivity, or with high-risk HPV DNA positivity and normal cytology or with postcoital bleeding and/or suspicious appearance of the cervix underwent colposcopy and colposcopic-directed biopsy. Results: Of the 520 women included in the study, the prevalence of the hr-HPV types is as follows: HPV 16 (29%), HPV 18 (13.7%), other high-risk HPV (43.8%), and HPV 16 or 18 plus other hr-HPV (13.5%). Among patients diagnosed with ≥ CIN2, 36.3% had HPV 16 positivity, 21.8% had HPV 18, 24.2% had other hr-HPV and 17.7% had co-infection with HPV type 16 and 18 and other hr-HPV types. HPV 16 (Odds Ratio (OR) = 3.099, 95%Confidence Interval (CI) = 1.933–4.968), HPV 18 (OR = 4.834, 95% CI = 2.715–8.608), and co-infection with HPV 16 or 18 with other hr-HPV types (OR = 3.324, 95% CI = 1.851–5.969) were statistically significantly associated ≥ CIN2 on biopsy. Among patietns with normal cytology and positive for other hr-HPV types CIN2+ was detected in 10.3% of patients who underwent biopsy, but only 1.5%had CIN3 and no cancers were detected. Conclusion: Consistent with our national screening guidelines, the risk for CIN3+ for women with normal cytology but positive for hr-HPV types other than 16 and 18 is low. Re-testing these patients in one year appears acceptable.


Cervical intraepithelial neoplasia; Cervical cancer; High-risk HPV; Cytological abnormalities; Colposcopy

Cite and Share

Seda Şahin Aker,Batuhan Bakırarar,Andrea Tinelli,Fırat Ortaç. The effect of other high-risk HPV types on cervical intraepithelial neoplasia and cancer. European Journal of Gynaecological Oncology. 2022. 43(1);10-16.


[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Vaccarella S, Franceschi S, Snijders PJF, Herrero R, Meijer CJLM, Plummer M. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiology, Biomarkers & Prevention. 2010; 19: 503–510.

[3] Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, Boztas G, Semra Turan H, et al. Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. International Journal of Cancer. 2018; 142: 1952–1958.

[4] Fife KH, Cramer HM, Schroeder JM, Brown DR. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. Journal of Medical Virology. 2001; 64: 550–559.

[5] Pista A, Oliveira A, Verdasca N, Ribeiro F. Single and multiple human papillomavirus infections in cervical abnormalities in Portuguese women. Clinical Microbiology and Infection. 2011; 17: 941–946.

[6] Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. The Journal of Infectious Diseases. 2011; 203: 910–920.

[7] Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New England Journal of Medicine. 2003; 348: 518–527.

[8] Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. American Journal of Obstetrics and Gynecology. 2007; 197: 346–355.

[9] Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV Infection among Females in the United States. Journal of the American Medical Association. 2007; 297: 813.

[10] Carrillo-García A, Ponce-de-León-Rosales S, Cantú-de-León D, Fragoso-Ontiveros V, Martínez-Ramírez I, Orozco-Colín A, et al. Impact of human papillomavirus coinfections on the risk of high-grade squamous intraepithelial lesion and cervical cancer. Gynecologic Oncology. 2014; 134: 534–539.

[11] Vaccarella S, Herrero R, Snijders PJF, Dai M, Thomas JO, Hieu NT, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. International Journal of Epidemiology. 2008; 37: 536–546.

[12] Tang Y, Zheng L, Yang S, Li B, Su H, Zhang L. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a crosssectional five years study in non-vaccinated women. Virology Journal. 2017; 14: 84.

[13] Torres-Poveda K, Ruiz-Fraga I, Madrid-Marina V, Chavez M, Richardson V. High risk HPV infection prevalence and asso-ciated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program. BMC Cancer. 2019; 19: 1205.

[14] Liu SS, Leung RCY, Chan KKL, Cheung ANY, Ngan HYS. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. Journal of Clinical Microbiology. 2010; 48: 758–764.

[15] Castle PE, Sadorra M, Garcia F, Holladay EB, Kornegay J. Pilot study of a commercialized human papillomavirus (HPV) geno-typing assay: comparison of HPV risk group to cytology and histology. Journal of Clinical Microbiology. 2006; 44: 3915–3917.

[16] Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. International Journal of Cancer. 2011; 128: 927–935.

[17] van der Graaf Y, Molijn A, Doornewaard H, Quint W, van Doorn L, van den Tweel J. Human papillomavirus and the long-term risk of cervical neoplasia. American Journal of Epidemiology. 2002; 156: 158–164.

[18] Gilham C, Sargent A, Kitchener HC, Peto J. HPV testing compared with routine cytology in cervical screening: Long-term follow-up of ARTISTIC RCT. Health Technology Assessment. 2019; 23: 1–43.

[19] Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S, et al. Worldwide distribution of human papillo-mavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366: 991–998.

[20] Gultekin M, Dundar S, Keskinkilic B, Turkyilmaz M, Ozgul N, Yuce K, et al. How to triage HPV positive cases: Results of four million females. Gynecologic Oncology. 2020; 158: 105–111.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time